Ibiglustat (L-Malic acid)

TargetMol
Product Code: TAR-T11599
Supplier: TargetMol
CodeSizePrice
TAR-T11599-1mg1mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11599-5mg5mg£197.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11599-10mg10mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11599-25mg25mg£381.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11599-50mg50mg£532.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11599-100mg100mg£732.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Ibiglustat (L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase. Ibiglustat (L-Malic acid) can be used in studies about PD Parkinson?s disease, SRT in Fabry?s and Gaucher?s.
CAS:
1629063-78-0
Formula:
C24H30FN3O7S
Molecular Weight:
523.57
Pathway:
Metabolism
Purity:
0.9979
SMILES:
[C@H](CC(O)=O)(C(O)=O)O.C(NC(O[C@H]1C2CCN(C1)CC2)=O)(C)(C)C=3N=C(SC3)C4=CC=C(F)C=C4
Target:
Transferase

References

1. Glucosylceramide Synthase Inhibitors. WO 2015089067 A1. 2. Iva Stojkovska, et al. Molecular mechanisms of ?-synuclein and GBA1 in Parkinson?s disease. Cell Tissue Res. 2017. 3. Christoph Arenz, et al. Recent advances and novel treatments for sphingolipidoses. Future Med. Chem. (2017) 9(14), 1687?1700. 4. Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37(6):1013-22.